Lifetime Risk Factors for Pre- and Post-Bronchodilator Lung Function Decline. A Population-based Study

Bui, Dinh; Perret, Jennifer L; Walters, E. Haydn; Abramson, Michael J.; Burgess, John A.; Bui, Minh; Bowatte, Gayan; Lowe, Adrian J.; Russell, Melissa; Alif, Sheikh M; Thompson, Bruce; Hamilton, Garun S.; Giles, Graham G.; Thomas, Paul S.; Morrison, Stephen; Johns, DP; Knibbs, Luke D.; Zock, Jan Paul; Marcon, Alessandro; Garcia‐Aymerich, Judith; Erbas, Bircan; Jarvis, Déborah; Svanes, Cecilie; Lodge, Caroline

doi:10.1513/annalsats.201904-329oc

Cited by 29 publications

(32 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Moreover, Bui and colleagues have recently shown that baseline asthma was associated with accelerated decline in both pre-and post-bronchodilator FEV 1 . 16 The observation that children with better initial lung function at study entry exhibited a loss of lung function is similar to other studies. 4,7,11 Their frequency of severe exacerbation leading to emergency department visit was not different, and they had a better level of control at their last visit, than children with tracking of lung function.…”

Section: Discussionsupporting

confidence: 87%

Longitudinal assessment of loss and gain of lung function in childhood asthma

Mahut¹,

Bokov

Beydon

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The Childhood Asthma Management Program study revealed that 25.7% of children with mild to moderate asthma exhibit a loss of lung function. The objective was to assess the trajectories of function by means of serial FEV1 in asthmatic children participating in out-of-hospital follow-up. Methods: A total of 295 children (199 boys) who had undergone at least 10 spirometry tests from the age of 8 were selected from a single-center open cohort. The annualized rate of change (slope) for prebronchodilator FEV1 (percent predicted) was estimated for each participant and three patterns were defined: significantly positive slope, significantly negative slope, and null slope (non-significant P-value in the Pearson test). The standard deviation (SD) of each individual slope was recorded as a variability criterion of FEV1. Results: The median (25th and 75th percentile) age at inclusion and the last visit was 8.5 (8.2, 9.3) and 15.4 (14.8, 16.0) years, respectively. Tracking of function (null slope) was observed in 68.8% of the children, while 27.8% showed a loss of function (negative slope) and 3.4% showed a gain in function (positive slope). The children characterized by loss of function depicted a better initial function and a lower FEV1 variability during their follow-up than children with tracking or gain of lung function. At the last visit, these children were characterized by a lower lung function than children with tracking or gain of lung function. Conclusion: Children with a better initial FEV1 value and less FEV1 variability are more prone to loss of lung function.

show abstract

Section: Discussionsupporting

confidence: 87%

Longitudinal assessment of loss and gain of lung function in childhood asthma

Mahut¹,

Bokov

Beydon

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Recently, their use has been more rigorously regulated due to increasing knowledge about their carcinogenicity and toxicity [16,17]. Regarding lung health, some studies reported associations between exposure to solvents and respiratory symptoms [18], chronic obstructive pulmonary disease (COPD) [19] or a decrease in lung function [20][21][22]. Until now, there is limited evidence on the specific association between occupational exposures to solvents and asthma [23][24][25][26][27].…”

Section: Introductionmentioning

confidence: 99%

Occupational Exposures to Organic Solvents and Asthma Symptoms in the CONSTANCES Cohort

Sit

Letellier

Iwatsubo

et al. 2021

IJERPH

View full text Add to dashboard Cite

Solvents are used in many workplaces and may be airway irritants but few studies have examined their association with asthma. We studied this question in CONSTANCES (cohort of ‘CONSulTANts des Centres d’Examens de Santé’), a large French cohort. Current asthma and asthma symptom scores were defined by participant-reported respiratory symptoms, asthma medication or attacks, and the sum of 5 symptoms, in the past 12 months, respectively. Lifetime exposures to 5 organic solvents, paints and inks were assessed by questionnaire and a population-based Job-Exposure Matrix (JEM). Cross-sectional associations between exposures and outcomes were evaluated by gender using logistic and negative binomial regressions adjusted for age, smoking habits and body mass index. Analyses included 115,757 adults (54% women, mean age 47 years, 9% current asthma). Self-reported exposure to ≥1 solvent was significantly associated with current asthma in men and women, whereas using the JEM, a significant association was observed only in women. Significant associations between exposures to ≥1 solvent and asthma symptom score were observed for both self-report (mean score ratio, 95%CI, women: 1.36, 1.31–1.42; men: 1.34, 1.30–1.40) and JEM (women: 1.10, 1.07–1.15; men: 1.14, 1.09–1.18). Exposure to specific solvents was significantly associated with higher asthma symptom score. Occupational exposure to solvents should be systematically sought when caring for asthma.

show abstract

“…This should target primary preventive therapeutic strategies, with mediation(s) introduced prophylactically at a much earlier stage in middle age, and to address basic pathogenic mechanism of both airway destruction/obstruction and the concurrent lung cancer risk. Those selected for trials of this approach in the first instance would be those who can be shown with spirometric monitoring to have a more rapid “pre-COPD” downhill trajectory of lung function airflow indices [ 117 ].…”

Section: Discussionmentioning

confidence: 99%

The Underappreciated Role of Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease and Its Strong Link to Lung Cancer

et al. 2021

View full text Add to dashboard Cite

The World Health Organisation reported COPD to be the third leading cause of death globally in 2019, and in 2020, the most common cause of cancer death was lung cancer; when these linked conditions are added together they come near the top of the leading causes of mortality. The cell-biological program termed epithelial-to-mesenchymal transition (EMT) plays an important role in organ development, fibrosis and cancer progression. Over the past decade there has emerged a substantial literature that also links EMT specifically to the pathophysiology of chronic obstructive pulmonary disease (COPD) as primarily an airway fibrosis disease; COPD is a recognised strong independent risk factor for the development of lung cancer, over and above the risks associated with smoking. In this review, our primary focus is to highlight these linkages and alert both the COPD and lung cancer fields to these complex interactions. We emphasise the need for inter-disciplinary attention and research focused on the likely crucial roles of EMT (and potential for its inhibition) with recognition of its strategic place mechanistically in both COPD and lung cancer. As part of this we discuss the future potential directions for novel therapeutic opportunities, including evidence-based strategic repurposing of currently used familiar/approved medications.

show abstract

Lifetime Risk Factors for Pre- and Post-Bronchodilator Lung Function Decline. A Population-based Study

Cited by 29 publications

References 44 publications

Longitudinal assessment of loss and gain of lung function in childhood asthma

Longitudinal assessment of loss and gain of lung function in childhood asthma

Occupational Exposures to Organic Solvents and Asthma Symptoms in the CONSTANCES Cohort

The Underappreciated Role of Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease and Its Strong Link to Lung Cancer

Contact Info

Product

Resources

About